Verbatim response from Perplexity
On GLP-1 medications, most patients lose 5–10% of body weight by month 3 and reach 15–20% total loss by 12–18 months of continued treatment, with weight loss typically plateauing after 6–12 months [1][4][6]. However, sustainability depends heavily on continued use: stopping the drug leads to rapid regain, with patients recovering about 60% of lost weight within one year and up to 75% long-term unless therapy continues [3][5].
How Fast You Lose Weight
- Appetite reduction begins in 1–2 weeks, with measurable weight loss appearing by weeks 2–4 [6].
- Real-world data shows:
- ~5.9% loss at 3 months (semaglutide)
- ~10.9% at 6 months
- ~17.6% at 12 months for those who stay on the drug [4].
- Clinical trial averages:
- Semaglutide 2.4 mg: ~17.3% loss at 68 weeks [3].
- Tirzepatide: ~16–18% loss at 12–18 months [3][8][9].
- Liraglutide: modest 4–5% loss [8].
Is It Sustainable?
| Scenario | Weight Loss Outcome | Key Evidence |
|---|---|---|
| Continued treatment | 15–25% loss sustained for 2+ years | STEP-5 trial: maintenance up to 104 weeks [1] |
| Stopping medication | Regain 60% in 1 year, 75% long-term | Model predicts plateau at 75% regain [5] |
| After 2 years off drug | Most retain at least some loss (often 20–25% of acute loss) | Real-world: stabilized trajectories after 12 months off [2] |
| With lifestyle changes | 25% of weight loss may persist long-term | Even after stopping, ~4–5% of baseline weight lost permanently [5] |
Critical Factors for Long-Term Success
- Medication persistence: Those on treatment for a full year lose significantly more than short-duration users [15].
- Higher initial BMI and treating obesity vs. diabetes improve outcomes [15].
- Lifestyle integration: GLP-1s alone are insufficient; they must pair with nutrition, exercise, and behavioral changes for sustainable habits [12].
- Drug choice: Semaglutide and tirzepatide show superior efficacy over liraglutide [15][8].
Bottom Line
GLP-1s produce rapid, significant weight loss (15–20% in 1–1.5 years), but it is not sustainable without ongoing therapy for most patients. Obesity is now viewed as a chronic disease requiring long-term pharmacological management, similar to diabetes or hypertension [3]. If you consider stopping, expect regain within months, though some benefit (4–5% of baseline) may persist long-term [5].